natgillin/translations-raw huggingface dataset:
moving a plurality of cutter blades parallel each other, alternately in one direction and in the opposite one; 
pomicanje mnoštva reznih noževa međusobno paralelno, naizmjence u jednom smjeru i u suprotnom smjeru;
and L2 both represent direct bonds; 
i L2 oba predstavljaju izravne veze;
and R3 independently represent: 
i R3 neovisno predstavljaju:
R5aa to R5aj independently represent at each occurrence, H, 
aa do R5aj neovisno predstavljaju pri svakoj pojavi, H,
to B13 independently represent a direct bond, O, S or N(RN8); 
do B13 neovisno predstavljaju izravnu vezu, O, S ili N(RN8);
A compound selected from the group comprising: 
Spoj naznačen time da je izabran iz skupine koju čine:
A compound of formula lyd as defined in any one of Claims 1 to 7 for use in the treatment of a condition or disorder ameliorated by the inhibition of the A1 receptor or the A2a receptor wherein the condition or disorder is selected from: heart failure; kidney failure; oedema; cancer; diabetes; diarrhea; macular degeneration; depression; cognitive function diseases; a neurodegenerative disease; an attention related disorder; extra pyramidal syndrome; a disorder of abnormal movement; cirrhosis; liver fibrosis; fatty liver; dermal fibrosis; a sleep disorder; stroke; brain injury or neuroinflammation; and addictive behaviour. 
Spoj s formulom lyd kako je definirano u bilo kojem od zahtjeva 1 do 7 naznačen time da je za uporabu za liječenje stanja ili poremećaja koji se može poboljšati inhibicijom A1 receptora ili A2a receptora pri čemu stanje ili poremećaj su odabrani od: zastoja srca; zatajenja bubrega; edema; raka; dijabetesa; proljeva; makularne degeneracije; depresije; bolesti kognitivnih funkcija; neurodegenerativne bolesti; poremećaja povezanog s pozornošću; ekstra piramidalnog sindroma; poremećaja abnormalnih pokreta; ciroze; fibroze jetre; masne jetre; dermalne fibroze; poremećaja spavanja; moždanog udara; ozljede mozga ili neuroupale; te ovisničkog ponašanja.
Use as claimed in Claim 10, or compound for use as claimed in Claim 9, wherein the condition or disorder is ameliorated by the inhibition of the A2a receptor and is selected from depression; cognitive function diseases; a neurodegenerative disease; an attention related disorder; extra pyramidal syndrome; a disorder of abnormal movement; cirrhosis; liver fibrosis; fatty liver; dermal fibrosis; a sleep disorder; stroke; brain injury or neuroinflammation; and addictive behaviour. 
Uporaba prema zahtjevu 10, ili spoj za uporabu prema zahtjevu 9, naznačeni time da stanje ili poremećaj koji poboljšava inhibicijom A2a receptora i je odabrano od depresije; bolesti kognitivnih funkcija; neurodegenerativne bolesti; poremećaja povezanog s pozornošću; ekstra piramidalnog sindroma; poremećaja abnormalnih pokreta; ciroze; fibroze jetre; masne jetre; dermalne fibroze; poremećaja spavanja; moždanog udara; ozljede mozga ili neuroupale; te ovisničkog ponašanja.
Use as claimed in Claim 10 or Claim 11, or compound for use as claimed in Claim 9 or Claim 11, wherein the condition or disorder is migraine. 
Uporaba prema zahtjevu 10 ili zahtjevu 11, ili spoj za uporabu prema zahtjevu 9 ili zahtjevu 11, naznačeni time da stanje ili poremećaj je migrena.
Use, or compound for use as claimed in Claim 13, wherein the condition or disorder ameliorated by the inhibition of the A2a receptor is Parkinson's disease. 
Uporaba, ili spoj za uporabu prema zahtjevu 13, naznačeni time da stanje ili poremećaj koji se može poboljšati inhibicijom A2a receptor je Parkinsonova bolest.
Use as claimed in Claim 10 or Claim 11, or compound for use as claimed in Claim 9 or Claim 11, wherein the condition or disorder ameliorated by the inhibition of the A2a receptor is addictive behaviour or ADHD. 
Uporaba prema zahtjevu 10 ili zahtjevu 11, ili spoj za uporabu prema zahtjevu 9 ili zahtjevu 11, naznačeni time da stanje ili poremećaj koji se može poboljšati inhibicijom A2a receptor je ovisno ponašanje ili ADHD.
Compound for use as claimed in Claim 9 or Claim 11, or use as claimed in Claim 10 or Claim 11, wherein the condition or disorder ameliorated by the inhibition of the A1 receptor is mitigation of kidney damage caused by acute renal failure, oedema, heart failure, chronic renal disease and/or cirrhosis. 
Spoj za uporabu prema zahtjevu 9 ili zahtjevu 11, ili uporaba prema zahtjevu 10 ili zahtjevu 11, naznačeni time da stanje ili poremećaj koji se može poboljšati inhibicijom A1 receptor je ublažavanje oštećenja bubrega uzrokovanog akutnim zatajenjem bubrega, edem, zatajenje srca, kronična bolest bubrega i/ili ciroza.
A compound of formula lyd as defined in any one of Claims 1 to 7 for use in mitigating kidney damage caused by acute renal failure, oedema, heart failure, chronic renal disease and/or cirrhosis. 
Spoj s formulom lyd kako je definirano u bilo kojem od zahtjeva 1 do 7 naznačena time da je za uporabu za ublažavanje oštećenja bubrega uzrokovanog akutnim zatajenjem bubrega, edema, zatajenja srca, kronične bolesti bubrega i/ili ciroze.
The use of compound of formula lyd as defined in any one of Claims 1 to 7 for the manufacture of a medicament for mitigating kidney damage caused by acute renal failure, oedema, heart failure, chronic renal disease and/or cirrhosis. 
Uporaba spoja s formulom lyd kako je definirano u bilo kojem od zahtjeva 1 do 7 naznačen time da je za proizvodnju lijeka za ublažavanje oštećenja bubrega uzrokovanog akutnim zatajenjem bubrega, edema, zatajenja srca, kronične bolesti bubrega i/ili ciroze.
for compounds of formula lyd in which B represents a nitrogen-containing HetBB group that is attached via a nitrogen atom within the ring system, reaction of a compound of formula XIX, wherein X4a represents a suitable leaving group, L1 represents a direct bond, R1 represents H, and A represents the requisite substituted pyridine-4-yl group as defined in Claim 1, with a compound of formula XXXIV, HetB1-H XXXIV wherein HetB1 takes the same definition as HetBB as defined above, except that HetB1 is a nitrogen-containing heterocycle that is attached to the H-atom depicted for the compound of formula XXXIV via a nitrogen atom in the heterocycle; and 
za spojeve s formulom lyd u kojoj B predstavlja HetBB skupinu koja sadrži dušik koji je vezan preko dušikovog atoma u sklopu sustava prstena, reakciju spoja s formulom XIX, [image] pri čemu X4a predstavlja pogodnu izlaznu skupinu, L1 predstavlja izravnu vezu, R1 predstavlja H, i A predstavlja potrebnu supstituiranu piridin-4-il skupinu kako je definirano u zahtjevu 1, sa spojem s formulom XXXIV, [image] pri čemu HetB1 ima isto značenje kao HetBB kako je definirano iznad, osim što je HetB1 heterocikal koji sadrži dušik koji je vezan na H-atom prikazan za spoj s formulom XXXIV preko dušikovog atoma u heterociklu; te
B1, and B2 are independently adenine, guanine, thymine, cytosine, uracil or modified nucleobases. 
i B2 su nezavisno adenin, guanin, timin, citozin, uracil ili modificirane nukleobaze.
A pharmaceutical composition comprising a therapeutically effective amount of a compound of claims 1 to 5 in combination with a pharmaceutically acceptable carrier or excipient. 
Farmaceutska kompozicija koja sadrži terapeutski efikasnu količinu spoja prema patentnim zahtjevima 1 do 5 u kombinaciji sa farmaceutski prihvatljivim nosačem ili ekscipijensom.
Food formulation according to claim 1, characterised in that the said glycogen has a molecular weight of approximately 2,500,000 Daltons. 
Prehrambena formulacija prema zahtjevu 1, naznačena time, da navedeni glikogen ima molekularnu masu od otprilike 2 500 000 Daltona.
Food formulation according to claim 6, characterised in that the said nutritional element is selected from the group comprising carbohydrates, proteins, amino acids and derivatives, lipids, phospholipids, vitamins and mineral salts. 
Prehrambena formulacija prema zahtjevu 6, naznačena time, da je navedeni nutritivni element odabran iz skupine koju čine ugljikohidrati, proteini, aminokiseline i njihovi derivati, lipidi, fosfolipidi, vitamini i mineralne soli.
Food formulation according to any one of the preceding claims, characterised in that the said formulation is in solid form or in aqueous solution. 
Prehrambena formulacija prema bilo kojem od prethodnih zahtjeva, naznačena time, da je navedena formulacija u krutom obliku ili u obliku vodene otopine.
Food formulation according to any one of the preceding claims, characterised in that the said food formulation is selected from the group comprising a complete foodstuff, a food supplement, a nutritional solution for gastro-enteric administration, a nutritional solution for parenteral administration, or a foodstuff or supplement for diabetic individuals. 
Prehrambena formulacija prema bilo kojem od prethodnih zahtjeva, naznačena time, da je navedena prehrambena formulacija odabrana iz skupine koju čine cjelovita namirnica, dodatak prehrani, nutritivna otopina za gastroenteričku primjenu, nutritivna otopina za parenteralnu primjenu, ili namirnica ili dodatak prehrani za dijabetičare.
Use of glycogen according to claim 11 or 12, characterised in that the said food formulation is in solid form or in aqueous solution. 
Uporaba glikogena prema zahtjevu 11 ili 12, naznačena time, da je navedena prehrambena formulacija u krutom obliku ili je u obliku vodene otopine.
Use of glycogen according to any one of the preceding claims from 11 to 13, characterised in that the said food formulation is selected from the group comprising a complete foodstuff, a food supplement, a nutritional solution for gastro-enteric administration, a nutritional solution for parenteral administration, or a foodstuff or supplement for diabetic individuals. 
Uporaba glikogena prema bilo kojem od zahtjeva 11 do 13, naznačena time, da je navedena prehrambena formulacija odabrana iz skupine koju čine cjelovita namirnica, dodatak prehrani, nutritivna otopina za gastroenteričku primjenu, nutritivna otopina za parenteralnu primjenu, ili namirnica ili dodatak prehrani za dijabetičare.
Biodegradable composition according to Claim 4, wherein the heterocyclic aromatic compound is 2,5 -furanedicarboxylic acid. 
Biorazgradljivi pripravak prema zahtjevu 4, naznačen time da heterociklički aromatski spoj je 2,5-furandikarboksilna kiselina.
A system according to claim 1, the at least one wave deflecting member (7) being curved. 
Sustav sukladno zahtjevu 1, barem jedan članak za odbijanje vala (7) je zakrivljen.
Floor panel according to any of the preceding claims, characterized in that the lock-up body (14) is a pivotable body. 
Podni panel sukladno bilo kojem od prethodnih zahtjeva, naznačen time što sadrži dio na pritisak (15) koji lateralno djeluje na tijelo za zaključavanje (14).
A compound of formula (VII): or an enantiomer, diastereomer, tautomer, or pharmaceutically-acceptable salt or solvate thereof, wherein the symbols have the following meaning and are, for each occurrence, independently selected: 
[image] i [image] . Spoj formule V, [image] ili njegova farmaceutski prikladna sol, gdje simboli imaju sljedeća značenja i, za svako pojavljivanje, se biraju nezavisno:
A compound of formula VI: or an enantiomer, diastereomer, tautomer, or pharmaceutically-acceptable salt or solvate thereof, wherein the symbols have the following meaning and are, for each occurrence, independently selected: 
Spoj formule VIII: [image] ili njegov enantiomer, dijastereomer, tautomer, ili njegova farmaceutski prikladna sol ili solvat, gdje simboli imaju sljedeća značenja i, za svako pojavljivanje, se biraju nezavisno:
in case of (5) the compound is for treating relapsed cancer in a subject and is used as an adjuvant therapy following surgery; or in case of (6) the compound is for treating or preventing cancer metastasis in a subject and is used as an adjuvant therapy following surgery. 
u slučaju (5) spoj je za liječenje relapsa raka u subjekta i koristi se kao adjuvansa terapija nakon operacije; ili u slučaju (6) spoj je za liječenje ili prevenciju metastaza raka u subjekta i koristi se kao adjuvansa terapija nakon operacije.
load bearing frame beams (1, 1'), the height of which defines the height of the wall structure in the vertical direction, 
nosive okvirne grede (1, 1’), čija visina određuje visinu zidne strukture u vertikalnom smjeru,
fixing profiles (2, 2') which are attached to the frame beams (1, 1'), and which fixing profiles (2, 2') are essentially horizontal with respect to the height direction of the wall structure, 
profili za fiksiranje (2, 2’) koji su pričvršćeni na grede okvira (1, 1’), i koji profili za fiksiranje (2, 2’) su u osnovi horizontalni u odnosu na smjer visine zidne strukture, naznačena time što nadalje sadrži
A wall structure according to claim 1, characterised in that in the wall plate (3, 3', 4, 4') 
Zidna struktura sukladno zahtjevu 1, naznačena time što u zidnoj ploči (3, 3’, 4, 4’)
A wall structure according to claim 1 or 2, characterised in that the core layer of the wall plates (3, 3', 4, 4') is extruded polystyrene and the surface layers are made of a combination of grout and reinforcing mesh. 
Zidna struktura sukladno zahtjevu 1 ili 2, naznačena time što je jezgreni sloj zidnih ploča (3, 3’, 4, 4’) ekstrudirani polistired a površinski slojevi su načinjeni od šljunka i mreže za pojačavanje.
A wall structure according to any of the preceding claims, characterised in that the side edges of the wall plates (3, 3', 4, 4') arranged in the vertical direction one on top of the other that are arranged against each other comprise tongues and grooves, which tongues and grooves are arranged to each other and inside which tongue and groove joint the fixing profile (2, 2') is arrangeable in such a manner that the wall plates (3, 3', 4, 4') are tightly against each other. 
Zidna struktura sukladno bilo kojem od prethodnih zahtjeva, naznačena time što bočni rubovi zidnih ploča (3, 3’, 4, 4’) u biti su horizontalni u smjeru odnosno na smjer visine zidne strukture i bočne rubove zidnih ploča (3, 3’, 4, 4’) organizirene u vrtikalnom smjeru jedna iznad druge koje su organizirane jedna nasuprot druge sadrže jezičce i utore, koji jezičci i utori su organizirani jedan prema drugome i unutar kojeg spoja jezičca i utora profil za fiksiranje (2, 2’) je moguće organizirati tako da su zidne ploče (3, 3’, 4, 4’) tijesno jedna uz drugu.
A wall structure according to any of the preceding claims, characterised in that a groove or grooves (7, 7') into which the fixing profile is arrangeable have/has been arranged in the core layer of the side edge of the wall plate that is horizontal in the wall structure. 
Zidna struktura sukladno bilo kojem od prethodnih zahtjeva, naznačena time što utor ili utori (7, 7’) u koje se može pričvrstiti profil za fiksiranje je/su organizirani u središnjem sloju bočnog ruba zidne ploče koja je horizontalna u zidnoj strukturi.
A wall structure according to any of the preceding claims, characterised in that the fixing profile (2, 2') is made of metal, such as of sheet metal having a thickness of 0.2 - 3 mm. 
Zidna struktura sukladno bilo kojem od prethodnih zahtjeva, naznačena time što je profil za fiksiranje (2, 2’) načinjen od metala, kao što je list metala debljine 0.2 - 3 mm.
A wall structure according to any of the preceding claims, characterised in that in the wall plates have been arranged consecutively in the horizontal direction of the wall structure in such a manner that the side edges of the wall plates have been arranged against one another. 
Zidna struktura sukladno bilo kojem od prethodnih zahtjeva, naznačena time što su zidne ploče organizirane konsekutivno u horizontalnom smjeru zidne ploče na način da su kratki rubovi zidnih ploča organizirani jedan nasuprot drugoga.
the load bearing frame beams (1, 1') of the wall structure are arranged into place, which frame beams define the height of the wall structure in the vertical direction, and 
nosive okvirne grede (1, 1’) zidne strukture smještene su na mjesto, koje okvirne grede definiraju visinu zidne strukture u vertikalnom smjeru, naznačen time što
A method according to claim 10, characterised in that the side edges of the wall plates (3, 3', 4, 4') arranged against each other comprise tongues and grooves, which tongues and grooves are arranged to each other and inside which tongue and groove joint the fixing profile (2, 2') is arrangeable in such a manner that the plates are tightly against each other. 
Postupak sukladno zahtjevu 10, naznačen time što bočni rubovi zidnih ploča (3, 3’, 4, 4’) organizirani jedan nasuprot drugoga sadrže jezičce i utore, koji jezičci i utori su organizirani jedan prema drugome i unutar kojeg jezičca i utora je moguće urediti fiksirajući profil (2, 2’) na način da su ploče tijesno jedna kraj druge.
A method according to any of the preceding claims 10-12, characterised in that the long side edges of the wall plates (3, 3', 4, 4') are arranged essentially in the horizontal direction with respect to the height direction of the wall structure. 
Postupak sukladno bilo kojem od prethodnih zahtjeva 10-12, naznačen time što su bočni rubovi zidnih ploča (3, 3’, 4, 4’) organizirani su u osnovi u horizontalnom smjeru u odnosu na smjer visine zidne strukture.
The compound of claim 1 or claim 2, wherein R2 is 4-sulfamoylphenyl. 
Tvar iz patentnog zahtjeva 1 ili patentnog zahtejva 2, pri čemu je R2 4-sulfamoilfenil.
The compound of any one of claims 1-4, or a pharmaceutically acceptable salt, for use as a medicament. 
Tvar iz bilo kojeg od patentnih zahtjeva 1-4, ili farmaceutski prihvatljiva sol, za uporabu kao lijek.
A pharmaceutical composition, comprising a therapeutically effective amount of at least one compound of any one of claims 1-5, and a pharmaceutically acceptable carrier. 
Farmaceutski sastav, sadrži terapijski učinkovitu količinu barem jedne tvari iz bilo kojeg od patentnih zahtjeva 1-5, i farmaceutski prihvatljivi nosač.
The compound for use of claim 5, wherein the medicament is a neuroprotective drug or a neuroenhancing drug; or a neuroregenerative drug or an immunomodulator. 
Tvar za uporabu iz patentnog zahtjeva 5, pri čemu je medikament neuroprotektivni lijek ili neuropobuđujući lijek; ili neuroregenerativni lijek ili imunomodulator.
The compound for use of claim 5 or pharmaceutical composition of claim 6, wherein the medicament or pharmaceutical composition has a combination of neuroprotective and immunomodulatory effects. 
Tvar za uporabu iz patentnog zahtjeva 5 ili farmaceutski sastav iz patentnog zahtjeva 6, pri čemu medikament ili farmaceutski sastav ima kombinaciju neuroprotektivnog i imunomodulatornog učinka.
Use of the compound of any one of claims 1-5 as an active ingredient in the manufacture of a medicament for the prevention or treatment of a disease selected from: neurological diseases, preferentially neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, Alzheimer's disease, Friedreich's ataxia, Huntington's disease, Dementia with Lewy bodies, and spinal muscular atrophy; nerve inflammation, such as multiple sclerosis or neuromyelitis optica; major depressive disorder; schizophrenia; glaucoma; peripheral neuropathy, such as diabetic or AIDS neuropathy; and cancer, such as glioblastoma, astrocytoma, meduloblastoma, neurinoma, neuroblastoma, meningioma, colon cancer, pancreatic cancer, breast cancer, prostate cancer, leukemia, acute lymphocytic leukemia, osteosarcoma, hepatocellular carcinoma, ovarian carcinoma, lung adenocarcinoma, and esophagic carcinoma. 
Uporaba tvari iz bilo kojeg od patentnih zahtjeva 1-5 kao aktivnog sastojka u proizvodnji medikamenta za prevenciju ili liječenje bolesti odabrane između: neuroloških bolesti, poželjno neurodegenerativnih poremećaja, kao što su amiotrofna lateralna skleroza (ALS), Parkinsonova bolest, Alzheimerova bolest, Friedrichova ataksija, Huntingtonova bolest, Demencija s Lewyjevim tjelešcima, spinalna muskularna atrofija; upale živca, kao što je multipla skleroza ili optički neuromijelitis, velikih depresivnih poremećaj; shizofrenije; glaukoma; periferne neuropatije, kao što je dijabetička ili AIDS neuropatija; i raka, kao što je glioblastom, astrocitom, meduloblastom, neurinom, neuroblastom, meningiom, rak kolona, rak gušterače, rak dojke, rak prostate, leukemija, akutna limfocitna leukemija, osteosarkom, hepatocelularni karcinom, karcinom jajnika, adenom pluća i karcinom jednjaka.
The compound for use of claim 13, wherein the nerve growth factor receptor is TrkA receptor or p75 receptor. 
Tvar za uporabu navedenu u patentnom zahtjevu 13, pri čemu je receptor živčanog faktora rasta TrkA receptor ili p75 receptor.
The compound for use of claim 16, wherein the brain-derived neurotrophic factor receptor is TrkB receptor or p75 receptor. 
Tvar za uporabu u skladu s patentnim zahtjevom 16, pri čemu je receptor neurotrofnog faktora moždanog porijekla TrkB receptor ili p75 receptor.
A method of preparing a pharmaceutical composition, comprising admixing an effective amount of a compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof, with a pharmaceutically acceptable carrier. 
Metoda za pripravu farmaceutskog sastava, obuhvaća umješavanje učinkovite količine tvari iz bilo kojeg od patentnog zahtjeva 1-5, ili njene farmaceutski prihvatljive soli, u farmaceutski prihvatljivi nosač.
The system of claim 1 or claim 2, wherein the first carrier piece (170) includes at least one latch (174, 176, 178, 180, 182) and the second carrier piece (172) includes at least one recess (184, 186, 188, 190, 192), the at least one latch disposed in the at least one recess to attach the first and second carrier pieces together. 
Sustav prema zahtjevu 1 ili zahtjevu 2, naznačen time da prvi nosivi dio (170) sadrži najmanje jedan zasun (174, 176, 178, 180, 182) i drugi nosivi dio (172) sadrži najmanje jedno udubljenje (184, 186, 188, 190, 192), te najmanje jedan zasun smješten u najmanje jednom udubljenju tako da zajedno spaja prve i druge dijelove nosača.
The system of any one of the preceding claims, wherein the top cap (300) comprises a hinged lever (302) having a storage state disposed along the carrier (106), and an operative state disposed across the top cap. 
Sustav prema bilo kojem od prethodnih zahtjeva, naznačen time da gornji poklopac (300) sadrži zglobnu polugu (302) koja ima stanje za pohranu smješteno uzduž nosača (106), te radno stanje postavljeno uzduž gornjeg poklopca.
a relative amount of glycans carrying bisecting N-acetylglucosamine (bisGlcNAc) of at least 20 % of the total amount of glycans attached to FSH in the preparation; and 
relativnu količinu glikana koji nose bisektirajući N-acetilglukozamin (bisGlcNAc) od najmanje 20% od ukupne količine glikana vezanih za FSH u preparatu; i
comprises a relative amount of glycans carrying fucose of at least 30% of the total amount of glycans attached to FSH in the preparation; and/or 
sadrži relativnu količinu glikana koji nose fukozu od najmanje 30% od ukupne količine glikana vezanih za FSH u preparatu; i/ili
is a diverse glycosylation pattern, wherein the FSH in the preparation comprises at least 35 different glycan structures, wherein each one of these different glycan structures has a relative amount of at least 0.1% of the total amount of glycan structures of the FSH in the preparation. 
je drugačija shema glikozilacije, naznačeno time da FSH u preparatu sadrži najmanje 35 različitih glikanskih struktura, pri čemu svaka od ovih različitih glikanskih struktura sadrži relativnu količinu od najmanje 0.1% od ukupne količine glikanskih struktura FSH u preparatu.
a relative amount of glycans carrying bisecting N-acetylglucosamine (bisGlcNAc) of at least 25 %, preferably at least 30 %, of the total amount of glycans attached to FSH in the preparation; and 
relativnu količinu glikana koji nose bisektirajući N-acetilglukozamin (bisGlcNAc) od najmanje 25%, a prije svega najmanje 30% od ukupne količine glikana vezanih za FSH u preparatu; i
a relative amount of 2,6-coupled sialic acid of at least 50%, preferably at least 53%, of the total amount of sialic acids. 
relativnu količinu 2,6-kuplovana sijalinske kiseline od najmanje 50%, a prije svega najmanje 53% od ukupne količine sijalinskih kiselina.